London, United Kingdom · Founded 2020 · Privately Held (backing)
Developer of a glycan-based vaccine technology intended to revolutionize animal vaccinology and combat antimicrobial resistance. ArkVax is based in London, United Kingdom and was founded in 2020.
Last price · $/share
—
Implied valuation
—
Total raised
—
Last round
—
Team — not yet on record
No current team members for ArkVax are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of ArkVax with a free account
·Watch ArkVax: the Monday email on marks, rounds and moves
